Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Pyridostigmine→

Pyridostigmine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
155-97-5
Molecular formula
C9H13N2O2+
Molecular weight
181.21 g/mol
Drug class
Reversible acetylcholinesterase inhibitorCholinesterase inhibitor
Mechanism of action
Reversibly inhibits cholinesterase, reducing acetylcholine hydrolysis and facilitating cholinergic transmission at the neuromuscular junction.
Indications / reported uses
  • Myasthenia gravis

Sources: DailyMed — Pyridostigmine bromide tablets prescribing information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Pyridostigmine Environmental Risk Assessment (ERA) (the Pyridostigmine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.